Literature DB >> 6398033

In vitro assessment of the antimalarial activity of chloroquine and its major metabolites.

A F Aderounmu.   

Abstract

A quantitative assessment of the antimalarial activity of chloroquine and its two major metabolites, desethylchloroquine (DEC) and bis-desethylchloroquine (bis-DEC), was made using a semi-automated microdilution technique. Two isolates of Plasmodium falciparum were used: the multi-drug resistant Vietnam Smith LA 137 strain and the chloroquine-sensitive Camp LA 137 strain. Mefloquine served as the standard for the Vietnam Smith strain and chloroquine for the Camp strain. Chloroquine and DEC demonstrated nearly equivalent activities in their inhibition of the growth of the chloroquine-sensitive Camp strain. Bis-DEC was less active since its ID50 was more than twice that of chloroquine. Against the chloroquine-resistant Vietnam Smith strain, DEC showed a three-fold loss of activity and bis-DEC showed no activity at concentrations as high as 340 ng ml-1. A combination of chloroquine and DEC showed an additive effect against both the Vietnam Smith and Camp strains.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6398033     DOI: 10.1080/00034983.1984.11811868

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  12 in total

1.  Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine.

Authors:  Juliana Martha Sá; Olivia Twu; Karen Hayton; Sahily Reyes; Michael P Fay; Pascal Ringwald; Thomas E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

2.  In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum.

Authors:  S Fu; A Björkman; B Wåhlin; D Ofori-Adjei; O Ericsson; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 4.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

5.  Protein binding of chloroquine enantiomers and desethylchloroquine.

Authors:  D Ofori-Adjei; O Ericsson; B Lindström; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

Review 6.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine.

Authors:  Matthew M Ippolito; Jeffrey M Jacobson; Michael M Lederman; Markus Winterberg; Joel Tarning; Theresa A Shapiro; Charles Flexner
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

8.  Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria.

Authors:  P A Peeters; K de Leest; W M Eling; D J Crommelin
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

9.  Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax.

Authors:  Anne C G Almeida; Maria C B Puça; Erick F G Figueiredo; Laila R Barbosa; Yanka E A R Salazar; Emanuelle L Silva; Marcelo A M Brito; André M Siqueira; José L F Vieira; Marcus V G Lacerda; Wuelton M Monteiro; Gisely C Melo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

10.  Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border.

Authors:  Richard Höglund; Younis Moussavi; Ronnatrai Ruengweerayut; Anurak Cheomung; Angela Äbelö; Kesara Na-Bangchang
Journal:  Malar J       Date:  2016-02-29       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.